title: Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience.
abstract: OBJECTIVE
  To investigate whether gender affects therapeutic response by exenatide twice a day (BID) in type 2 diabetes by using a database concerning patients monitored by five outpatient clinics in Tuscany, Italy.
  
  
  METHODS
  We considered a cohort of 315 (154 male/161 female) patients experiencing therapeutic failure while on oral therapy (metformin, or combination therapy metformin + sulphonylureas), who were given exenatide (10 μg/BID) and who fully completed 4 months, 8 months, and 12 months of follow-ups.
  
  
  RESULTS
  Among patients stratified by gender and well matched for age, body mass index, and hemoglobin A1c (HbA1c), it was found that the length of disease was longer in females than in males (12 ± 8 years versus 10 ± 7 years; P = 0.037), and the ratio of patients on metformin to those on combination therapy was higher in men (P = 0.018). Target glycemic response (1-year HbA1c ≤ 7%) was achieved in a significantly higher proportion of males than females (38% versus 27%; χ(2) = 4.66; P = 0.03). Target weight loss expressed as 1-year weight percent fall from baseline ≥ 75th percentile (8.5%) was significantly higher in females at 8 and 12 months (P < 0.05; for both). One-year glycemic target response was inversely related to baseline HbA1c levels and diabetes duration among males, while metformin therapy (compared to oral combination therapy) was a significant predictor of better glycemic targets among females. Homeostasis model assessment-B, measured in 117 patients, predicted hypoglycemic response only in women (P = 0.009). Target 1-year weight loss was predicted by longer diabetes duration among males and by lower baseline HbA1c among females. Finally, no significant difference between genders was noted as to gastrointestinal side effects after exenatide therapy.
  
  
  CONCLUSIONS
  According to this "real world" experience, predictors of glycemic control and body weight loss after 12 months of exenatide BID therapy are different between genders in type 2 diabetes.
authors: Diabetes Unit, Spedali Riuniti, Pistoia, Italy.
authors: Roberto
authors: R
authors: Anichini
authors: Sabrina
authors: S
authors: Cosimi
authors: Alberto
authors: A
authors: Di Carlo
authors: Paola
authors: P
authors: Orsini
authors: Alessandra
authors: A
authors: De Bellis
authors: Giuseppe
authors: G
authors: Seghieri
authors: Flavia
authors: F
authors: Franconi
authors: Fabio
authors: F
authors: Baccetti
keywords: GLP-1 agonist therapy; exenatide BID; real world setting; type 2 diabetes
references: Ann Intern Med. 1996 Jan 1;124(1 Pt 2):136-45
references: 8554206
references: Diabetes Obes Metab. 2008 Jun;10 Suppl 1:25-32
references: 18435671
references: Regul Pept. 2008 Feb 7;146(1-3):4-11
references: 17889380
references: Curr Diab Rep. 2007 Oct;7(5):340-7
references: 18173966
references: Am Heart J. 2006 Jul;152(1):27-38
references: 16824829
references: Am J Epidemiol. 1990 Sep;132(3):501-13
references: 2389754
references: Diabetes. 2004 Sep;53(9):2492-500
references: 15331566
references: Diabetologia. 2012 Jan;55(1):80-7
references: 21861177
references: Diabetes Care. 2012 Jun;35(6):1364-79
references: 22517736
references: Diabet Med. 2009 Sep;26(9):837-46
references: 19719703
references: JAMA. 2007 Jul 11;298(2):194-206
references: 17622601
references: Lancet. 1998 Sep 12;352(9131):837-53
references: 9742976
references: BMC Endocr Disord. 2010 Dec 09;10:20
references: 21143938
references: Diabetologia. 1993 Aug;36(8):741-4
references: 8405741
references: J Clin Invest. 1998 Feb 1;101(3):515-20
references: 9449682
references: Expert Opin Investig Drugs. 2008 Jun;17(6):845-53
references: 18491986
references: Eur J Endocrinol. 2009 Jun;160(6):909-17
references: 19318378
references: Lancet. 1998 Sep 12;352(9131):854-65
references: 9742977
references: Diabetes Metab. 2010 Nov;36(5):381-8
references: 20598606
references: Diabetes Res Clin Pract. 2008 Apr;80(1):134-8
references: 18077049
references: Exp Clin Endocrinol Diabetes. 2007 Sep;115(8):491-4
references: 17853331
references: Diabetes Metab. 2001 Nov;27(5 Pt 1):563-71
references: 11694855
references: Endocrinology. 2003 Dec;144(12):5149-58
references: 12960095
references: Diabetes Care. 2004 Jun;27(6):1487-95
references: 15161807
references: Postgrad Med. 2012 Jul;124(4):21-32
references: 22913891
references: J Biol Chem. 2003 Jan 3;278(1):471-8
references: 12409292
references: Clin Endocrinol (Oxf). 2009 Mar;70(3):343-53
references: 18771570
references: Horm Metab Res. 2005 Feb;37(2):111-7
references: 15778929
references: Curr Med Res Opin. 2011 Dec;27(12):2335-42
references: 22085180
references: Drugs. 2012 Aug 20;72(12):1679-707
references: 22867046